UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis

British journal of cancer, 2008-01, Vol.98 (2), p.294-299

2008

Volltextzugriff (PDF)

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

Annals of oncology, 2018-10, Vol.29, p.viii404-viii405

2018

Volltextzugriff (PDF)

Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

Annals of oncology, 2018-10, Vol.29, p.viii223-viii223

2018

Volltextzugriff (PDF)

Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.S204-S205

2016

Volltextzugriff (PDF)

The Use of Reirradiation in Locally Recurrent, Nonmetastatic Rectal Cancer

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E192-E193

2016

Volltextzugriff (PDF)

A Phase I/II Study of Capecitabine (Cape), Oxaliplatin (Ox), Panitumumab (Pmab), and External Beam Radiation Therapy (RT) for Patients With Esophagogastric Carcinoma (EC)

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S42-S42

2012

Volltextzugriff (PDF)

Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis?

Colorectal disease, 2013-11, Vol.15 (11), p.e654-e658

2013

Volltextzugriff (PDF)

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-Gastric Diseases (PROCEED): Assessment of Pathologic Response in a Prospective, Phase II Single-Arm Trial

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.S12-S12

2023

Volltextzugriff (PDF)

Carcinoma of the Ampulla of Vater: Patterns of Failure after Resection and Possible Benefit of Adjuvant Radiotherapy

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S195-S196

2010

Volltextzugriff (PDF)

A Phase I Study of Capecitabine, Oxaliplatin, Panitumumab, and External Beam Radiation Therapy (RT) for Patients with Esophagogastric Carcinoma (EC)

International journal of radiation oncology, biology, physics, 2009, Vol.75 (3), p.S57-S57

2009

Volltextzugriff (PDF)

1213P DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

Annals of oncology, 2022-09, Vol.33, p.S1103-S1104

2022

Volltextzugriff (PDF)

O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577

Annals of oncology, 2023-06, Vol.34, p.S183-S183

2023

Volltextzugriff (PDF)

1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

Annals of oncology, 2021-09, Vol.32, p.S1048-S1049

2021

Volltextzugriff (PDF)

1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

Annals of oncology, 2021-09, Vol.32, p.S1045-S1046

2021

Volltextzugriff (PDF)

P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer

Annals of oncology, 2017-09, Vol.28, p.v181-v182

2017

Volltextzugriff (PDF)

Carcinoma of the Ampulla of Vater: Patterns of Failure after Resection and Possible Benefit of Adjuvant Radiotherapy

International journal of radiation oncology, biology, physics, 2008, Vol.72 (1), p.S277-S277

2008

Volltextzugriff (PDF)

Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.E238-E239

2019

Volltextzugriff (PDF)

Validation of the Patient Care Monitor (Version 2.0): A Review of System Assessment Instrument for Cancer Patients

Journal of pain and symptom management, 2010-10, Vol.40 (4), p.545-558

2010

Volltextzugriff (PDF)

LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study

Annals of oncology, 2020-09, Vol.31, p.S1193-S1194

2020

Volltextzugriff (PDF)

1139PDNovel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer

International journal of radiation oncology, biology, physics, 2018-11, Vol.102 (3), p.S180-S180

2018

Volltextzugriff (PDF)

1188PDMargetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

123PEvaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1189PDDeterminants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Annals of oncology, 2019-10, Vol.30, p.v485-v485

2019

Volltextzugriff (PDF)

1 – 25 von 120

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(117)
Mit Volltextzugriff
(115)

Publikationsform

Artikel
(119)
Berichte
(1)

Sprache

Englisch
(120)

Erscheinungsjahr

n.n

Thema

Science & Technology
(34)
Life Sciences & Biomedicine
(32)
Humans
(24)
Oncology
(21)
Male
(15)
Female
(14)
Middle Aged
(13)
Tumors
(12)
Aged
(11)
Colorectal Cancer
(11)
Medicine
(11)
Cancer
(10)
Metastasis
(10)
Patients
(10)
Adult
(9)
Cancer Research
(8)
Medicine & Public Health
(8)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Biological And Medical Sciences
(7)
Chemotherapy
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Oxygen for relief of dyspnoea in mildly- or non-hypoxaemic patients with cancer: a systematic review and meta-analysis

Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

Biomarker-guided enrichment of the antitumor activity of margetuximab (M) plus pembrolizumab (P) in patients with advanced HER2+ gastric adenocarcinoma (GEA)

Interim Acute Toxicity Analysis and Surgical Outcomes of Neoadjuvant Gemcitabine/nab-Paclitaxel and Hypofractionated Image Guided Intensity Modulated Radiation Therapy in Resectable and Borderline Resectable Pancreatic Cancer (ANCHOR) Study

The Use of Reirradiation in Locally Recurrent, Nonmetastatic Rectal Cancer

A Phase I/II Study of Capecitabine (Cape), Oxaliplatin (Ox), Panitumumab (Pmab), and External Beam Radiation Therapy (RT) for Patients With Esophagogastric Carcinoma (EC)

Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis?

Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-Gastric Diseases (PROCEED): Assessment of Pathologic Response in a Prospective, Phase II Single-Arm Trial

Carcinoma of the Ampulla of Vater: Patterns of Failure after Resection and Possible Benefit of Adjuvant Radiotherapy

A Phase I Study of Capecitabine, Oxaliplatin, Panitumumab, and External Beam Radiation Therapy (RT) for Patients with Esophagogastric Carcinoma (EC)

1213P DKN-01 and tislelizumab + chemotherapy as first-line (1L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

O-7 Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577

1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial

1381P Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577

P2 study of ADXS11-001 Immunotherapy in patients with persistent/recurrent, surgically unresectable locoregional, or metastatic squamous cell anal cancer

Carcinoma of the Ampulla of Vater: Patterns of Failure after Resection and Possible Benefit of Adjuvant Radiotherapy

Imaging & Biomarker Correlates on Outcomes in a Phase II Trial of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Radiotherapy (HIGRT) in Potentially Resectable Pancreas Cancer

Validation of the Patient Care Monitor (Version 2.0): A Review of System Assessment Instrument for Cancer Patients

LBA9_PR Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study

1139PDNovel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial

Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer

1188PDMargetuximab (M) + pembrolizumab (P) for treatment of patients (pts) with HER2+ gastroesophageal adenocarcinoma (GEA) post-trastuzumab (T): Survival analysis

123PEvaluation of tumour microenvironment identifies immune correlates of response to combination immunotherapy with margetuximab (M) and pembrolizumab (P) in HER2+ gastroesophageal adenocarcinoma (GEA)

1189PDDeterminants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

1189PD - Determinants of response of HER2+ gastric cancer (GC) vs gastroesophageal junction adenocarcinoma (GEJ) to margetuximab (M) plus pembrolizumab (P) post trastuzumab (T)

Suchergebnisse filtern